Retinal Degeneration
A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)
Subtype terms (4)
More specific conditions that are subtypes of Retinal Degeneration in the MeSH hierarchy.
- Macular Degeneration
276 drugs (97 approved, 179 experimental)
- Retinal Drusen
17 drugs (9 approved, 8 experimental)
- Retinal Dystrophies
14 drugs (4 approved, 10 experimental)
- Retinoschisis
11 drugs (5 approved, 6 experimental)
Drugs by status
Phase 4 trials (2)
Phase 3 trials (3)
Phase 2 trials (17)
Phase 1 trials (8)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (15)
- Adverum Biotechnologies, Inc.
- Genentech
- Allergan
- AmpliPhi Biosciences Corporation
- Southeast Clinical Research Associates, LLC
- Tyrogenex
- National Eye Institute (NEI)
- University of London
- Seoul National University
- University of L'Aquila
- Lions Eye Institute
- Catholic University of Sacred Heart, Rome
- Gyroscope Therapeutics
- Editas Medicine, Inc.
- Gemini Therapeutics, Inc.
Organization Involved with Phase 1 Indications (7)